Newsletter | October 30, 2026

10.30.26 -- Why Clinical Trial Design Matters For MSC Success

FOCUS ON CLINICAL TRIALS

Why Clinical Trial Design Matters For MSC Success

During this segment of Cell & Gene Live, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics; Michael Schuster, Director of Business Development, Mesoblast; and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. share how recent negative iPSC-derived MSC clinical data should be interpreted, including the potential impact of trial design, patient selection, dosing, and the challenges of demonstrating efficacy in difficult indications.

Why Receptor Occupancy Assays Shape Clinical Pharmacodynamic Decisions

Receptor occupancy (RO) assays assess drug-target engagement and support PK/PD modeling. Accurate RO requires customized assays using stabilized blood to monitor CD6 modulation in autoimmune therapy.

Optimizing The Channel Strategy For Your CGT

Build a channel strategy tailored to your cell or gene therapy. Explore distribution, provider access, and fulfillment options that can reduce complexity and improve patient access.

How In-Home Trials Can Shift The Pediatric Rare Disease Research Landscape

DCT solutions are not just about bringing the trial to the patient’s home and reducing logistical burdens, but also strengthening the family-researcher connection.

CLINICAL TRIALS SOLUTIONS

•

Protocol-Driven, Customized Site Solution Strategy - Parexel International

•

Central Laboratory Solutions - LabConnect

•

Support For Efficient FDA Interactions - Veristat, Inc.

•

Streamline Medication Management And Simplify Complex Workflows - McCreadie Group

FOCUS ON SUPPLY CHAIN

New Container Protects Bulk Frozen Biopharmaceuticals

Learn more about a flexible freeze container that maintains package integrity after freezing at -86 °C (-123 °F) through its durable design, minimizing product loss due to package failure.

Connect With Cell & Gene: